{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T07:09:57Z","timestamp":1714115397886},"reference-count":86,"publisher":"Impact Journals, LLC","issue":"47","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2020,11,24]]},"DOI":"10.18632\/oncotarget.27819","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T15:52:49Z","timestamp":1606233169000},"page":"4371-4386","source":"Crossref","is-referenced-by-count":5,"title":["Treatment of elderly patients with refractory\/relapsed multiple myeloma: oral drugs adherence and the COVID-19 outbreak"],"prefix":"10.18632","volume":"11","author":[{"given":"Fl\u00e1via Dias","family":"Xavier","sequence":"first","affiliation":[{"name":"Hematology, Hospital Universitario de Brasilia-UNB\/Ebserh, Brasilia, DF, Brazil"},{"name":"Hospital Sirio Libanes, Centro de Oncologia, Unidade Brasilia, Brasilia, DF, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando Sergio Blumm","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Hospital Sirio Libanes, Centro de Oncologia, Unidade Brasilia, Brasilia, DF, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo Martins","family":"Abreu","sequence":"additional","affiliation":[{"name":"Medical Affairs, Takeda Distribuidora Ltda., S\u00e3o Paulo, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","reference":[{"key":"1","article-title":"SEER Cancer Statistics Review (CSR), 1975-2014","author":"Feuer","year":"2017","journal-title":"Natl Cancer Inst"},{"key":"2","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"36","author":"Anderson","year":"2011","journal-title":"N Engl J Med"},{"key":"3","article-title":"IBGE | Proje\u00e7\u00e3o da popula\u00e7\u00e3o","author":"IBGE","year":"2013","journal-title":"Instituto Brasileiro de Geografia e Estatistica"},{"key":"4","article-title":"World population prospects: The 2015 Revision, Key Findings and Advance Tables","author":"United Nations","year":"2015","journal-title":"United Nations"},{"key":"5","first-page":"87","article-title":"Maria de Lima Horta Pimentel VP. O desafio do envelhecimento populacional na perspectiva sist\u00eamica da sa\u00fade","volume":"4","author":"Barbosa","year":"2016","journal-title":"Banco Nac Desenvolv Econ\u00f4mico e Soc"},{"key":"6","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1200\/JCO.2008.20.8983","article-title":"Future of cancer incidence in the United States: Burdens upon an aging, changing nation","volume":"2","author":"Buchholz","year":"2009","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3324\/haematol.2015.129189","article-title":"Treatment of relapsed and refractory multiple myeloma","volume":"10","author":"Broijl","year":"2016","journal-title":"Haematologica"},{"key":"8","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients","volume":"2","author":"Russell","year":"2014","journal-title":"Leukemia"},{"key":"9","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","article-title":"Dramatically improved survival in multiple myeloma patients in the recent decade: Results from a Swedish population-based study","volume":"10","author":"Kristinsson","year":"2018","journal-title":"Haematologica"},{"key":"10","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/leu.2014.23","article-title":"Improved long-term survival in multiple myeloma up to the age of 80 years","volume":"2","author":"Landgren","year":"2014","journal-title":"Leukemia"},{"key":"11","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1","volume":"11","author":"Avet-Loiseau","year":"2011","journal-title":"Blood"},{"key":"12","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1182\/blood.V128.22.246.246","article-title":"Evaluation of Minimal Residual Disease (MRD) in Relapsed\/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone","volume":"12","author":"Qin","year":"2016","journal-title":"Blood"},{"key":"13","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/bjh.14787","article-title":"Elotuzumab plus lenalidomide\/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth","volume":"17","author":"Mateos","year":"2017","journal-title":"Br J Haematol"},{"key":"14","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1002\/cncr.31680","article-title":"Elotuzumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial","volume":"12","author":"Richardson","year":"2018","journal-title":"Cancer"},{"key":"15","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"37","author":"Gimsing","year":"2016","journal-title":"N Engl J Med"},{"key":"16","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"37","author":"Schecter","year":"2016","journal-title":"N Engl J Med"},{"key":"17","doi-asserted-by":"publisher","first-page":"8006","DOI":"10.1200\/JCO.2017.35.15_suppl.8006","article-title":"Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status","volume":"3","author":"Sonneveld","year":"2017","journal-title":"J Clin Oncol"},{"key":"18","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR","volume":"10","author":"Lee","year":"2018","journal-title":"Haematologica"},{"key":"19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomize, phase 3, open-label, multicentre study","volume":"1","author":"Suvorov","year":"2016","journal-title":"Lancet Oncol"},{"key":"20","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"1","author":"Minuk","year":"2017","journal-title":"Lancet Oncol"},{"key":"21","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"2","author":"O\u2019Gorman","year":"2019","journal-title":"Lancet Oncol"},{"key":"22","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"1","author":"Lee","year":"2014","journal-title":"Lancet Oncol"},{"key":"23","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"37","author":"Ben Yehuda","year":"2016","journal-title":"N Engl J Med"},{"key":"24","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/leu.2014.60","article-title":"Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma","volume":"2","author":"Hansson","year":"2014","journal-title":"Leukemia"},{"key":"25","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX","volume":"10","author":"Kaufman","year":"2018","journal-title":"Haematologica"},{"key":"26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"37","author":"Suvorov","year":"2015","journal-title":"N Engl J Med"},{"key":"27","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1182\/blood-2016-03-707596","article-title":"Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma","volume":"12","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"28","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/bjh.14549","article-title":"Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study","volume":"17","author":"Niesvizky","year":"2017","journal-title":"Br J Haematol"},{"key":"29","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"3","author":"Stewart","year":"2018","journal-title":"J Clin Oncol"},{"key":"30","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1016\/j.clml.2017.03.256","article-title":"Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"1","author":"Hajek","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"31","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"37","author":"Beksac","year":"2015","journal-title":"N Engl J Med"},{"key":"32","doi-asserted-by":"publisher","first-page":"djv370","DOI":"10.1093\/jnci\/djv370","article-title":"Financial Toxicity of Cancer Care: It\u2019s Time to Intervene","volume":"10","author":"Zafar","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/RMHP.S19801","article-title":"Adherence and health care costs","volume":"7","author":"McGuire","year":"2014","journal-title":"Risk Manag Healthc Policy"},{"key":"34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/BF00280102","article-title":"Measurement of patient compliance and the interpretation of randomized clinical trials","volume":"4","author":"Vander Stichele","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"35","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report","volume":"12","author":"Terpos","year":"2015","journal-title":"Blood"},{"key":"36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"11","author":"Vesole","year":"2010","journal-title":"Blood"},{"key":"37","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International Myeloma working group recommendations for the diagnosis and management of Myeloma-Related Renal Impairment","volume":"3","author":"Einsele","year":"2016","journal-title":"J Clin Oncol"},{"key":"38","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/ki.2012.65","article-title":"The implications of anatomical and functional changes of the aging kidney: With an emphasis on the glomeruli","volume":"8","author":"Rule","year":"2012","journal-title":"Kidney Int"},{"key":"39","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/ndt\/gfw079","article-title":"Prevalence of reduced kidney function and albuminuria in older adults: The Berlin initiative study","volume":"3","author":"Schaeffner","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"40","article-title":"Revlimid (Lenalidomide)","author":"Celgene Brasil Produtos Farmac\u00eauticos, Ltda","year":"2019","journal-title":"Bula"},{"key":"41","article-title":"Ninlaro (Ixazomib)","author":"Takeda Pharma Ltd","year":"2018","journal-title":"Bula"},{"key":"42","article-title":"Velcade (Bortezomib)","author":"Janssen-Cilag Farmac\u00eautica, Ltda","year":"2018","journal-title":"Bula"},{"key":"43","article-title":"PRESCRIBING INFORMATION POMALYST(pomalidomide) capsules, for oral use","author":"Celgene Corporation","year":"2013","journal-title":"U.S. Food and Drug Administration"},{"key":"44","unstructured":"Lexicomp Online, Drug Information Handbook. Hudson, Ohio: UpToDate, Levothyroxine, 2015."},{"key":"45","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"3","author":"Cavo","year":"2014","journal-title":"J Clin Oncol"},{"key":"46","article-title":"PRESCRIBING INFORMATION FARYDAK(panobinostat) capsules, for oral use","author":"Novartis Pharmaceuticals Corporation","year":"2015","journal-title":"U.S. Food and Drug Administration"},{"key":"47","article-title":"PRESCRIBING INFORMATION XPOVIOTM (selinexor) tablets, for oral use","author":"Karyopharm Therapeutics Inc","year":"2019","journal-title":"U.S. Food and Drug Administration"},{"key":"48","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","article-title":"Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens","volume":"11","author":"Bergsagel","year":"2009","journal-title":"Blood"},{"key":"49","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial","volume":"1","author":"Gonz\u00e1lez","year":"2010","journal-title":"Lancet Oncol"},{"key":"50","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1080\/10428194.2017.1365859","article-title":"Managing multiple myeloma in elderly patients","volume":"5","author":"Landau","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"51","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/bloodadvances.2017015545","article-title":"Analysis of carfilzomib cardiovascular safety profile across relapsed and\/or refractory multiple myeloma clinical trials","volume":"2","author":"Lenihan","year":"2018","journal-title":"Blood Adv"},{"key":"52","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1080\/10428190600948303","article-title":"The troublesome toxicity of peripheral neuropathy with thalidomide","volume":"4","author":"Prince","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"53","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma","volume":"2","author":"Avet-Loiseau","year":"2012","journal-title":"Leukemia"},{"key":"54","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"37","author":"Maisonneuve","year":"2007","journal-title":"Lancet"},{"key":"55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.blre.2010.10.003","article-title":"Management of older patients with multiple myeloma","volume":"2","author":"Palumbo","year":"2011","journal-title":"Blood Rev"},{"key":"56","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"37","author":"Grosicki","year":"2018","journal-title":"N Engl J Med"},{"key":"57","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study","volume":"1","author":"Cavet","year":"2011","journal-title":"Lancet Oncol"},{"key":"58","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"11","author":"Callea","year":"2010","journal-title":"Blood"},{"key":"59","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s40265-016-0573-4","article-title":"Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma","volume":"7","author":"Driessen","year":"2016","journal-title":"Drugs"},{"key":"60","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1200\/JCO.2012.46.2598","article-title":"Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: The Intergroupe Francophone du My\u00e9lome experience","volume":"3","author":"Pegourie","year":"2013","journal-title":"J Clin Oncol"},{"key":"61","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"12","author":"San Miguel","year":"2016","journal-title":"Blood"},{"key":"62","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/cncr.22855","article-title":"Time to first disease progression, but not b2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy","volume":"11","author":"Boccadoro","year":"2007","journal-title":"Cancer"},{"key":"63","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1002\/cncr.26662","article-title":"Durable remission with salvage second autotransplants in patients with multiple myeloma","volume":"11","author":"Qazilbash","year":"2012","journal-title":"Cancer"},{"key":"64","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"17","author":"Cavo","year":"2016","journal-title":"Br J Haematol"},{"key":"65","unstructured":"Leukemia & Lymphoma Society. Myeloma Oral Treatment Adherence Facts. Leukemia & Lymphoma Society. http:\/\/www.lls.org."},{"key":"66","article-title":"Oral Antimyeloma Therapy: Barriers to Patient Adherence and Tips for Improvement","author":"Sweiss","year":"2018","journal-title":"HOPA NEWS"},{"key":"67","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.2147\/PPA.S183187","article-title":"Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer?","volume":"1","author":"Salwender","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"68","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s41669-019-00184-9","article-title":"Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma","volume":"4","author":"Romanus","year":"2020","journal-title":"Pharmacoeconom Open"},{"key":"69","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1182\/blood.V128.22.5931.5931","article-title":"Assessing the Effect of Injectable or Oral Routes of Treatment Administration on Patient-Reported Outcomes and out-of-Pocket Costs Among Patients with Multiple Myeloma","volume":"12","author":"Rosenberg","year":"2016","journal-title":"Blood"},{"key":"70","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study","volume":"1","author":"Stewart","year":"2018","journal-title":"Lancet Oncol"},{"key":"71","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1634\/theoncologist.2017-0229","article-title":"FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy","volume":"2","author":"Pazdur","year":"2017","journal-title":"Oncologist"},{"key":"72","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1038\/s41375-018-0120-2","article-title":"Ninety-minute daratumumab infusion is safe in multiple myeloma","volume":"3","author":"Hofmeister","year":"2018","journal-title":"Leukemia"},{"key":"73","article-title":"Empliciti (Elotuzumab)","author":"Bristol-Myers Squibb Farmac\u00eautica, LTDA","year":"2017","journal-title":"Bula"},{"key":"74","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma","volume":"38","author":"Richter","year":"2019","journal-title":"N Engl J Med"},{"key":"75","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention","volume":"32","author":"McGoogan","year":"2020","journal-title":"JAMA"},{"key":"76","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"39","author":"Li","year":"2020","journal-title":"Lancet"},{"key":"77","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1001\/jama.2020.4683","article-title":"Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy","volume":"32","author":"Brusaferro","year":"2020","journal-title":"JAMA"},{"key":"78","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1470-2045(20)30217-5","article-title":"Cancer guidelines during the COVID-19 pandemic","volume":"2","author":"Burki","year":"2020","journal-title":"Lancet Oncol"},{"key":"79","article-title":"Coronavirus Disease COVID-19: EBMT Recommendations","author":"EBMT","year":"2020","journal-title":"EBMT"},{"key":"80","article-title":"COVID-19 and Multiple Myeloma: Frequently Asked Questions [Internet]","author":"Dhakal","year":"2020","journal-title":"American Society Of Hematology"},{"key":"81","doi-asserted-by":"publisher","first-page":"e435","DOI":"10.1016\/S2352-3026(20)30124-1","article-title":"Management of patients with multiple myeloma during the COVID-19 pandemic","volume":"7","author":"Mohty","year":"2020","journal-title":"Lancet Haematol"},{"key":"82","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: Self-maintaining and instrumental activities of daily living","volume":"9","author":"Brody","year":"1969","journal-title":"Gerontologist"},{"key":"83","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"4","author":"MacKenzie","year":"1987","journal-title":"J Chronic Dis"},{"key":"84","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","article-title":"Studies of Illness in the Aged: The Index of ADL: A Standardized Measure of Biological and Psychosocial Function","volume":"18","author":"Jaffe","year":"1963","journal-title":"JAMA"},{"key":"85","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"1","author":"Boccadoro","year":"2016","journal-title":"Lancet Oncol"},{"key":"86","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond","volume":"3","author":"Anderson","year":"2018","journal-title":"Leukemia"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27819","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T15:53:41Z","timestamp":1606233221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":86,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2020,11,24]]}},"alternative-id":["27819"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.27819","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,24]]}}}